TY - JOUR
T1 - Development of new prognostic model based on pretreatment βLRI and LLRI for stage IE/IIE upper aerodigestive tract ENKTL, nasal type
AU - Dai, Wumin
AU - Jia, Bo
AU - Yang, Jianliang
AU - Zhou, Shengyu
AU - Liu, Peng
AU - He, Xiaohui
AU - Qin, Yan
AU - Gui, Lin
AU - Zhang, Changgong
AU - Han, Xiaohong
AU - Sun, Yan
AU - Shi, Yuankai
N1 - Funding Information:
Financial support was provided by the Vice President for Research and Technology, Ferdowsi University of Mashhad. The study was made possible by the generous supports of the Jovain Industrial and Agricultural company, Khorasan-e-Razavi, Iran. The kind cooperation of the director (M.R. Frouzanmehr) and staff of the Movahed Gostaran Jovain, Khorasan-e-Razavi, Iran, is greatly acknowledged. We also would like to thank Dr A. Javadmanesh and Dr A. Mahmoudi for their technical assistance.
Publisher Copyright:
© Dai et al.
PY - 2017
Y1 - 2017
N2 - To identify simple non-invasive prognostic factors for extranodal natural killer/T cell lymphoma (ENKTL), we have investigated the prognostic value of pretreatment β2-microglobin to lymphocytes ratio index (βLRI) or lactate dehydrogenase to lymphocytes ratio index (LLRI), by analyzing the retrospective data from 211 ENKTL patients. Receiver operating characteristic (ROC) curve analysis was performed to determine the cut-off value of pretreatment βLRI and LLRI. The univariate analysis indicated that Ann Arbor Stage (p = 0.008), Eastern Cooperative Oncology Group score (ECOG) (p = 0.009), International Prognostic Index (IPI) (p = 0.023), βLRI (p = 0.003), LLRI (p = 0.04), neutrophil-lymphocyte ratio index (p = 0.025) and monocyte/granulocyte to lymphocyte ratio (p = 0.030) were significantly associated with overall survival (OS) in ENKTL patients. However, multivariate analysis demonstrated that only Ann Arbor Stage (p = 0.028), βLRI (p < 0.001) and LLRI (p = 0.006) were only correlated independently with OS. Furthermore, βLRI and LLRI based new prognostic model showed improved discrimination for stage IE/IIE upper aerodigestive tract in ENKTL patients than IPI and Korean Prognostic Index. Overall, our study concluded that new βLRI-based prognosis model is useful to stratify ENKTL patients and higher βLRI and LLRI can act as independent prognostic predictor candidates in early stage ENKTL.
AB - To identify simple non-invasive prognostic factors for extranodal natural killer/T cell lymphoma (ENKTL), we have investigated the prognostic value of pretreatment β2-microglobin to lymphocytes ratio index (βLRI) or lactate dehydrogenase to lymphocytes ratio index (LLRI), by analyzing the retrospective data from 211 ENKTL patients. Receiver operating characteristic (ROC) curve analysis was performed to determine the cut-off value of pretreatment βLRI and LLRI. The univariate analysis indicated that Ann Arbor Stage (p = 0.008), Eastern Cooperative Oncology Group score (ECOG) (p = 0.009), International Prognostic Index (IPI) (p = 0.023), βLRI (p = 0.003), LLRI (p = 0.04), neutrophil-lymphocyte ratio index (p = 0.025) and monocyte/granulocyte to lymphocyte ratio (p = 0.030) were significantly associated with overall survival (OS) in ENKTL patients. However, multivariate analysis demonstrated that only Ann Arbor Stage (p = 0.028), βLRI (p < 0.001) and LLRI (p = 0.006) were only correlated independently with OS. Furthermore, βLRI and LLRI based new prognostic model showed improved discrimination for stage IE/IIE upper aerodigestive tract in ENKTL patients than IPI and Korean Prognostic Index. Overall, our study concluded that new βLRI-based prognosis model is useful to stratify ENKTL patients and higher βLRI and LLRI can act as independent prognostic predictor candidates in early stage ENKTL.
KW - Beta2-microglobin to lymphocytes ratio index
KW - Extranodal natural killer/T cell lymphoma
KW - Lactate dehydrogenase to lymphocytes ratio index
KW - Prognosis
KW - Systemic immune-inflammation
UR - http://www.scopus.com/inward/record.url?scp=85019837585&partnerID=8YFLogxK
U2 - 10.18632/oncotarget.16720
DO - 10.18632/oncotarget.16720
M3 - Article
AN - SCOPUS:85019837585
VL - 8
SP - 34787
EP - 34795
JO - Oncotarget
JF - Oncotarget
SN - 1949-2553
IS - 21
ER -